Expert Perspectives on Fixed Duration Therapy with Venetoclax + Obinutuzumab

Opinion
Video

A panel of experts discuss the role of fixed duration therapy with venetoclax and obinutuzumab, outlining their general approach for patient selection.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on recent advances in the multidisciplinary approach to cancer.

      Subscribe Now!
      Recent Videos
      Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
      CLL Workshop Emphasizes Engaging Conversations on Shared Treatment Planning
      Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
      Navigating Treatment Decision-Making Challenges in CLL Management
      Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
      Asciminib Appears to Benefit All Chronic Myeloid Leukemia Subgroups
      Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
      Undetected MRD Confers Improved PFS With Ibrutinib Combo in CLL/SLL
      Greater direct access to academic oncologists may help address challenges associated with a lack of CAR T education in the community setting.
      Spreading Greater CAR T-Cell Therapy Education in the Community Setting
      Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
      Avoiding CAR T-Cell Collection Problems Following Bridging Therapies
      Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
      Academic/Community Collaboration May Help Facilitate CAR T Therapy Access
      A panel of 3 experts on CML
      Advancing CML Management Towards an Ideal Patient Journey
      A panel of 3 experts on CML
      Ensuring Informed CML Care from Diagnosis Onward
      A panel of 3 experts on CML
      CML Treatment: Scenarios that Necessitate Switching Therapy
      Related Content
      An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.

      Blinatumomab-Related ICANS Symptoms More Prevalent Than Prior Reports

      Russ Conroy
      April 11th 2025
      Article

      An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

      Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
      October 21st 2024
      Podcast

      A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

      Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

      HSCT Recipients Show Sustained Health Challenges Following Transplant

      Roman Fabbricatore
      March 25th 2025
      Article

      Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

      Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

      Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups

      Rahul Banerjee, MD, FACP;Noopur Raje, MD
      September 2nd 2024
      Podcast

      Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.

      The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.

      Pelabresib Plus Ruxolitinib Improves Spleen Responses in Myelofibrosis

      Roman Fabbricatore
      March 17th 2025
      Article

      The combination regimen was well tolerated in JAK inhibitor-naïve myelofibrosis, with instances of thrombocytopenia managed with dose modifications.

      Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.

      Orca-T Displays cGVHD-Free Survival Benefit in Hematologic Malignancies

      Roman Fabbricatore
      March 17th 2025
      Article

      Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.